The licensing and option agreement is the latest in a wave of large Western pharma partnerships with Chinese biotech, and covers an mRNA-encoded T-cell engager

The BTK inhibitor becomes the first of its class cleared for previously untreated chronic lymphocytic leukemia, expanding Lilly's oncology footprint into an ear

The clearance gives patients with advanced pancreatic cancer a new treatment option in a disease with few effective therapies.

Regulators are flagging compounded and unapproved GLP-1 products as demand for obesity drugs outpaces approved supply.

The screen points to genes whose activation lets tumors evade therapy, offering targets for combination strategies.

The work maps essential lncRNAs, a largely unexplored class of potential drug targets.

The pact adds to a run of China-focused licensing deals as Western pharma looks to refill oncology pipelines.

The clinical collaboration adds Datroway to Summit's pipeline in a combination study.

Ultragenyx's application was validated by the EMA as the company advances a gene therapy for the rare neurodegenerative disorder.

The metal-free balloon offers an alternative for treating narrowed arteries without leaving a permanent implant.

The new office signals a regulatory push to update how trials are designed and run.

Extrachromosomal DNA helps tumors adapt, and targeting it could open new therapeutic avenues.

The findings suggest biological sex shapes disease risk and lifespan through chromosome-level mechanisms.

Investor concerns over the CAR-T therapy's outlook weighed on the stock.

The regulator's green light moves another iPSC-derived cell therapy into human testing.

Moderna's index inclusion lifted sentiment across biotech, while debate continues over China's AI-driven drug discovery claims.

The direct-to-consumer model for the obesity drug has drawn pushback from local doctors and pharmacists.

The redesign aims to simplify a sprawling information ecosystem that required users to understand NIH's structure.